# GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

> **NCT07221214** · PHASE2 · RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- HIV
- Alcohol
- Smoking Cigarette
- Cardiovascular Disease Prevention

## Interventions

- **DRUG:** Semaglutide (Rybelsus®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221214
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2029-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221214, "GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07221214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*